Imunon Inc (IMNN)
1.31
+0.03
(+2.34%)
USD |
NASDAQ |
May 08, 10:38
Imunon Cash from Financing (TTM): -3.639M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -3.639M |
September 30, 2023 | -3.222M |
June 30, 2023 | -3.364M |
March 31, 2023 | 9.197M |
December 31, 2022 | 6.723M |
September 30, 2022 | 6.275M |
June 30, 2022 | 6.331M |
March 31, 2022 | 14.31M |
December 31, 2021 | 54.77M |
September 30, 2021 | 57.33M |
June 30, 2021 | 54.21M |
March 31, 2021 | 52.65M |
December 31, 2020 | 17.98M |
September 30, 2020 | 17.09M |
June 30, 2020 | 21.94M |
March 31, 2020 | 11.88M |
December 31, 2019 | 7.845M |
September 30, 2019 | 5.798M |
June 30, 2019 | 4.086M |
March 31, 2019 | 11.10M |
December 31, 2018 | 10.58M |
September 30, 2018 | 36.68M |
June 30, 2018 | 40.84M |
March 31, 2018 | 34.37M |
December 31, 2017 | 36.45M |
Date | Value |
---|---|
September 30, 2017 | 11.01M |
June 30, 2017 | 5.810M |
March 31, 2017 | 6.983M |
December 31, 2016 | 2.678M |
September 30, 2016 | 2.020M |
June 30, 2016 | 2.049M |
March 31, 2016 | 3.972M |
December 31, 2015 | 4.082M |
September 30, 2015 | 4.462M |
June 30, 2015 | 5.473M |
March 31, 2015 | 4.085M |
December 31, 2014 | 18.78M |
September 30, 2014 | 19.26M |
June 30, 2014 | 18.79M |
March 31, 2014 | 22.42M |
December 31, 2013 | 29.39M |
September 30, 2013 | 35.78M |
June 30, 2013 | 40.13M |
March 31, 2013 | 36.35M |
December 31, 2012 | 15.52M |
September 30, 2012 | 22.59M |
June 30, 2012 | 42.09M |
March 31, 2012 | 47.89M |
December 31, 2011 | 52.84M |
September 30, 2011 | 39.98M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-3.639M
Minimum
Dec 2023
57.33M
Maximum
Sep 2021
17.80M
Average
9.197M
Median
Mar 2023
Cash from Financing (TTM) Benchmarks
Avalo Therapeutics Inc | 25.04M |
iBio Inc | 10.68M |
Ocugen Inc | 20.88M |
Petros Pharmaceuticals Inc | 11.54M |
Moderna Inc | -821.00M |